SCHEMBL2470801

SCHEMBL2470801

O=C(CCO)Nc1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.66
MAPT P10636 2/20 0.66
HTT P42858 1/20 0.66
HDAC4 P56524 8/20 0.61
HDAC1 Q13547 8/20 0.61
HDAC7 Q8WUI4 8/20 0.61
HDAC11 Q96DB2 8/20 0.61
HDAC8 Q9BY41 8/20 0.61
HDAC6 Q9UBN7 8/20 0.61
HDAC9 Q9UKV0 8/20 0.61
HDAC5 Q9UQL6 8/20 0.61
HDAC3 O15379 7/20 0.61
HDAC2 Q92769 7/20 0.61
HDAC10 Q969S8 7/20 0.61
CYP3A4 P08684 3/20 0.61
KDM4E B2RXH2 1/20 0.61
BRD4 O60885 1/20 0.61
NCOR1 O75376 1/20 0.61
NR1I2 O75469 1/20 0.61
EGFR P00533 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19501262 0.92 TP53 (0.63) L3MBTL1MAPTHTTHDAC4HDAC1
SCHEMBL3342586 0.89 L3MBTL1 (0.80) L3MBTL1MAPTHTTHDAC4HDAC1
SCHEMBL4594453 0.88 HDAC8 (0.68) L3MBTL1MAPTHTTHDAC4HDAC1
SCHEMBL7837980 0.86 HDAC8 (0.71) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL10612618 0.85 MAPT (0.62) L3MBTL1MAPTHDAC4HDAC1HDAC7
SCHEMBL517309 0.84 HDAC4 (0.81) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL6296181 0.84 HDAC4 (0.75) L3MBTL1MAPTHTTHDAC4HDAC1
SCHEMBL7563467 0.84 HDAC8 (0.74) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL4403514 0.84 HDAC8 (0.74) HDAC4HDAC1HDAC7HDAC11HDAC8
SCHEMBL1162572 0.84 HDAC8 (0.74) HDAC4HDAC1HDAC7HDAC11HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9714560-B2 Protected scale inhibitors and methods relating thereto HALLIBURTON ENERGY SERVICES, INC. (US) 2017-07-25 US claimed
WO-2008132128-A2 SYNTHESIS OF A PHARMACEUTICALLY ACTIVE COMPOUND Solvay (Société Anonyme) (BE) 2008-11-06 WO claimed
US-6815398-B1 PRE- AND POSTEMERGENCE HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 2004-11-09 US claimed
EP-1242387-A1 SUBSTITUTED PHENYLURACILS AND THEIR USE AS HERBICIDES Bayer Aktiengesellschaft (DE) 2002-09-25 EP claimed
WO-2001034575-A1 SUBSTITUTED PHENYLURACILS AND THEIR USE AS HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 2001-05-17 WO claimed
WO-2023282236-A1 RARE EARTH COMPLEX 東ソー株式会社 2023-01-12 WO disclosed
CN-113533577-A Method for simultaneously determining blood concentration of vancomycin and aminophylline and application 淮安市妇幼保健院 2021-10-22 CN disclosed
US-20210070690-A1 CATALYST FOR CONVERTING ESTER TO AMIDE USING HYDROXYL GROUP AS ORIENTATION GROUP CHUBU UNIVERSITY EDUCATIONAL FOUNDATION (JP) 2021-03-11 US disclosed
EP-2920163-B1 PYRIDYLOXYAL ALKYL CARBOXAMIDES AND THEIR USE AS ENDOPARASITICIDES AND NEMATICIDE BAYER CROPSCIENCE AG (DE) 2018-05-02 EP disclosed
US-9714560-B2 Protected scale inhibitors and methods relating thereto HALLIBURTON ENERGY SERVICES, INC. (US) 2017-07-25 US disclosed
US-9556121-B2 Pyridyloxyalkyl carboxamides and use thereof as endoparasiticides and nematicides BAYER CROPSCIENCE AG (DE) 2017-01-31 US disclosed
US-20150291524-A1 PYRIDYLOXYALKYL CARBOXAMIDES AND USE THEREOF AS ENDOPARASITICIDES AND NEMATICIDES BAYER CROPSCIENCE AG (DE) 2015-10-15 US disclosed
US-6815398-B1 PRE- AND POSTEMERGENCE HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 2004-11-09 US disclosed
EP-1242387-A1 SUBSTITUTED PHENYLURACILS AND THEIR USE AS HERBICIDES Bayer Aktiengesellschaft (DE) 2002-09-25 EP disclosed
EP-0454501-B1 Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides SANKYO CO (JP) 2001-09-05 EP disclosed
WO-2001034575-A1 SUBSTITUTED PHENYLURACILS AND THEIR USE AS HERBICIDES BAYER AKTIENGESELLSCHAFT (DE) 2001-05-17 WO disclosed
EP-0839812-A1 Preparation of benzylthiazolidine derivatives Sankyo Company Limited (JP) 1998-05-06 EP disclosed
US-5387596-A Treating arteriosclerosis SANKYO COMPANY, LIMITED (JP) 1995-02-07 US disclosed
EP-0454501-A2 Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides Sankyo Company Limited (JP) 1991-10-30 EP disclosed
US-4886813-A INHIBITORS OF ANGIOTENSIN CONVERTING ENZYME OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) 1989-12-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210070690-A1 CATALYST FOR CONVERTING ESTER TO AMIDE USING HYDROXYL GROUP AS ORIENTATION GROUP EBP, NR1H3, APEH L3MBTL1 4155/4885MAPT 3930/4885HTT 1464/4885
US-20150291524-A1 PYRIDYLOXYALKYL CARBOXAMIDES AND USE THEREOF AS ENDOPARASITICIDES AND NEMATICIDES PLPBP, PFAS, PGLS L3MBTL1 1375/4885MAPT 4801/4885HTT 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.